--- title: 'Morning Brief — Friday, October 16, 2026' type: 'episode' url: 'https://doc.social/episodes/morning-brief-2026-10-16' show: 'doc social Morning Brief' show_url: 'https://doc.social/podcasts/morning-brief' published: '2026-10-16' audio: 'https://media.doc.social/podcasts/morning-brief/2026-10-16.mp3' --- # Morning Brief — Friday, October 16, 2026 J&J says DePuy Synthes separation remains on track for mid-2027 and it is leaning toward a spin-off; Q3 orthopaedics sales rose 3.2% to $2.34B while spine fell 0.9% · Kuros Biosciences raises 2026 guidance to 36-40% sales growth after nine-month sales of $141.8M (+40%) and starts MagnetOs production in Alpharetta, Georgia · Amber Implants begins the U.S. introduction of its VCFix Spinal System, a… ## Summary 4 stories this morning, for surgeons and the people who support them. - **J&J says DePuy Synthes separation remains on track for mid-2027 and it is leaning toward a spin-off; Q3 orthopaedics sales rose 3.2% to $2.34B while spine fell 0.9%** — J&J Q3 2026 results, October 13, 2026 (SEC 8-K exhibit 99.1: https://www.sec.gov/Archives/edgar/data/0000200406/000020040626000189/a2026q3exhibit991.htm): MedTech sales $8,642M, up 2.5%. CFO Joe Wolk's prepared remarks: 'we remain on track for the planned separation of DePuy Synthes by mid-2027' and 'we are leaning towards a spin as being the best option'; more detail at the Enterprise Business Review on December 8. ORTHOWORLD (October 15, 2026, https://www.orthoworld.com/depuy-synthes-on-track-for-mid-2027-spin-off-from-jj/): Q3 orthopaedics $2,344.5M (+3.2%); knees $385.4M (+2.5%), hips $419.1M (+3.2%), spine $206.3M (-0.9%), trauma $746.0M (+6.1%); nine-month spine -2%; MedTech EVP Tim Schmid attributed slower growth largely to the war in Iran, 'no longer limited to a handful of markets.' BNN Bloomberg and MassDevice also report the mid-2027 spin target. Follow-up to the 2026-09-15 episode on reported Apollo sale talks (~$20B); J&J's remarks do not mention a sale. [Source](https://www.jnj.com/media-center/press-releases/johnson-johnson-q3-2026-earnings-ceo-and-cfo-prepared-remarks) - **Kuros Biosciences raises 2026 guidance to 36-40% sales growth after nine-month sales of $141.8M (+40%) and starts MagnetOs production in Alpharetta, Georgia** — Kuros release, Schlieren, Switzerland, October 15, 2026: nine-month medical device sales USD 141.8M vs 101.1M (+40%); adjusted EBITDA USD 20.6M, 14.5% margin vs 12.1%; cash USD 19.6M. New 2026 guidance 36-40% sales growth and adjusted EBITDA margin above 14.5%; the H1 release (August 13, 2026) had guided at least 35% growth and about 14% margin, and confirmed 2028 targets of USD 300-330M. Alpharetta, Georgia site began commercial MagnetOs production in October, alongside Bilthoven, Netherlands. Trial enrollment: PROOF 97%, PRECISE 55%, ASTRA 18%. 2025 nine-month base of USD 101.1M corroborated by Moneycab (October 16, 2025). MagnetOs is cleared for use throughout the spine including interbody with an approved device, not as an osteoinductive graft. [Source](https://orthospinenews.com/2026/10/15/kuros-biosciences-increases-2026-annual-guidance-the-company-reports-40-year-over-year-increase-in-sales-in-the-first-nine-months-of-2026/) - **Amber Implants begins the U.S. introduction of its VCFix Spinal System, a pedicle-based expandable implant with cement for vertebral compression fractures** — ORTHOWORLD, October 14, 2026, citing Amber Implants' October 13, 2026 GlobeNewswire release: Amber began the U.S. introduction of VCFix after its first U.S. clinical use. VCFix combines a pedicle-based expandable implant with cement fixation in one percutaneous procedure, aiming to restore vertebral height and support the anterior and posterior columns; Amber calls it minimally invasive vertebral reconstruction. FDA 510(k) K250637, decision date May 30, 2025, product code NDN (vertebroplasty bone cement), per openFDA. Background: FDA Breakthrough designation 2021; 10-patient first-in-human study in Mechernich, Germany, enrolled by June 2024. Competitive context: Stryker's SpineJack (510(k) 2018; SAKOS RCT non-inferior to balloon kyphoplasty at 12 months) and balloon kyphoplasty. First-case site, surgeon and launch scale not disclosed in available sources. [Source](https://www.orthoworld.com/amber-implants-launches-vcfix-in-the-u-s/) - **HSS registry study at NASS 2026: robotic-arm MIS-TLIF associated with 16% lower in-hospital opioid use than navigation-guided MIS-TLIF in 804 patients** — HSS release, San Antonio, October 15, 2026, presented at the NASS Annual Meeting: prospectively maintained registry, 804 one- or two-level MIS-TLIF patients from 2017 to 2025, 601 robotic arm-assisted and 203 navigation-guided, adjusted for patient characteristics, surgeon and other factors. Robotic group: 16% lower total in-hospital opioid consumption, 21% lower in the first 24 hours, 57% lower likelihood of needing IV PCA; no significant difference in complications or length of stay. Robot platform not named; percentages only, no MME. Co-authors Sheeraz Qureshi and Kyle Morse. Also carried by Ortho Spine News the same day. Observational, framed as an association. [Source](https://news.hss.edu/hss-study-finds-robotic-assisted-lumbar-fusion-associated-with-lower-opioid-use-after-surgery/) ### Contribute to the Brief Faculty can send the show a note — a reaction to a paper, a correction, a read on a rule change — either written, which we shape for broadcast and read in the show's voice, or as a voice note under three minutes, which airs in your own voice. Send one from [Studio](https://next.doc.social/studio). Not on doc social yet? [Contribute a lecture or join the network](https://next.doc.social/contribute) — doc social is a clinical education platform for clinicians, and this show is one part of it. _Narration is synthesized. Reporting and editorial judgement are ours, and every story above links to its source._